Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
amoxicillin + clavulanic acid (GSK, d8c631)
- Development stage
- Phase 4
- Lead developer
- Sparsh Biotech
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Spotclav is a generic brand of co-amoxiclav, a combination antibiotic consisting of the beta-lactam antibiotic amoxicillin and the beta-lactamase inhibitor clavulanic acid (as potassium clavulanate). Manufactured by Sparsh Bio-Tech, Spotclav is administered orally to treat a wide variety of bacterial infections, including acute bacterial sinusitis, acute otitis media, community-acquired pneumonia, cystitis, pyelonephritis, skin and soft tissue infections, and bone and joint infections. Amoxicillin works by binding to and inhibiting penicillin-binding proteins (PBPs) involved in bacterial cell wall synthesis, leading to cell lysis. Clavulanic acid acts as a suicide inhibitor of beta-lactamase enzymes, preventing the degradation of amoxicillin by resistant bacteria and extending its spectrum of activity.
- Brand names
- Spotclav
- Other names
- amox-clavamoxicillin and clavulanate potassiumamoxicillin and clavulanic acidco-amoxiclav
02
Targets
Class A BL (Class A beta-lactamase)PBP (Penicillin-binding protein family)
Beyond the preview
Go deeper on amoxicillin + clavulanic acid (GSK, d8c631).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on amoxicillin + clavulanic acid (GSK, d8c631).